See more : Paraca Inc. (4809.T) Income Statement Analysis – Financial Results
Complete financial analysis of IR-Med Inc. (IRME) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IR-Med Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Japan Exchange Group, Inc. (8697.T) Income Statement Analysis – Financial Results
- Yangarra Resources Ltd. (YGRAF) Income Statement Analysis – Financial Results
- Hubei Three Gorges Tourism Group Co., Ltd. (002627.SZ) Income Statement Analysis – Financial Results
- Kelyniam Global, Inc. (KLYG) Income Statement Analysis – Financial Results
- Waterdrop Inc. (WDH) Income Statement Analysis – Financial Results
IR-Med Inc. (IRME)
About IR-Med Inc.
IR-Med Inc., a development stage medical device company, focuses on the development of infra-red light spectroscopy combined with artificial intelligence technology platform to address diagnostic or medical needs. It is developing PressureSafe, a handheld optical monitoring device to support early detection of pressure injuries to the skin and underlying tissue primarily caused by prolonged pressure associated with bed confinement; and Nobiotics, an otoscope to support physicians with an immediate indication as to whether mid-ear infection (Otitis Media), a common malady in children. The company is headquartered in Rosh Pina, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 17.00K | 10.00K | 5.00K | 1.00K | 2.00K | 0.00 |
| Gross Profit | -17.00K | -10.00K | -5.00K | -1.00K | -2.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.06M | 1.89M | 1.42M | 409.00K | 61.00K | 0.00 |
| General & Administrative | 2.03M | 1.98M | 1.29M | 316.00K | 150.00K | 0.00 |
| Selling & Marketing | 822.00K | 759.00K | 888.00K | 0.00 | 147.85K | 0.00 |
| SG&A | 2.85M | 2.74M | 2.18M | 316.00K | 148.00K | 900.00 |
| Other Expenses | 0.00 | 135.00K | 74.00K | 5.00K | 0.00 | 0.00 |
| Operating Expenses | 4.89M | 4.76M | 3.68M | 730.00K | 209.00K | 900.00 |
| Cost & Expenses | 4.91M | 4.76M | 3.68M | 730.00K | 211.00K | 900.00 |
| Interest Income | 0.00 | 6.00 | 5.00 | 9.00 | 4.00 | 0.00 |
| Interest Expense | 0.00 | 6.00K | 5.00K | 9.00K | 4.00K | 0.00 |
| Depreciation & Amortization | 17.00K | 10.00K | 5.00K | 1.00K | 2.00K | 0.00 |
| EBITDA | -4.89M | -4.75M | -3.67M | -729.00K | -209.00K | -900.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -4.91M | -4.76M | -3.68M | -730.00K | -211.00K | -900.00 |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.00K | 28.00K | -41.00K | -22.00K | -37.00K | 0.00 |
| Income Before Tax | -4.91M | -4.73M | -3.72M | -752.00K | -248.00K | -900.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 4.73M | 5.00K | 9.00K | 0.00 | 0.00 |
| Net Income | -4.91M | -9.46M | -3.72M | -761.00K | -248.00K | -900.00 |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.07 | -0.14 | -0.06 | -0.03 | -0.01 | -0.01 |
| EPS Diluted | -0.07 | -0.14 | -0.06 | -0.03 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 69.40M | 67.58M | 63.11M | 30.03M | 28.91M | 112.74K |
| Weighted Avg Shares Out (Dil) | 69.40M | 67.58M | 63.11M | 30.03M | 28.91M | 112.74K |
IR-MED to Conduct Usability Study with Methodist Healthcare of San Antonio for its PressureSafe Device Which is Slated for U.S. Launch in H1 2024
Rosh Pina, Israel, Sept. 26, 2023 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis technology platform to address significant healthcare needs, announced today it has signed a Clinical...
IR-MED Appoints Richard Serbin, Esq. to its Advisory Board
Rosh Pina, Israel, Sept. 13, 2023 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), a developer of a noninvasive AI-driven spectrographic analysis technology platform to address significant healthcare needs, announced today the appointment of Richard Serbin, Esq. to...
IR-MED Chairman & Interim CEO Issues Letter to Shareholders
Rosh Pina, Israel, Aug. 21, 2023 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive AI-driven infrared spectrographic analysis technology platform to address significant healthcare needs, today issued the following update to shareholders from its...
IR-MED's AI-Powered Infra-Red Spectrographic Decision Support System PressureSafe Device Demonstrates High Efficacy in Detecting Pressure Injuries with 96% Accuracy: Potential to Set a New Standard of Care
Rosh Pina, Israel, July 17, 2023 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive AI-driven Infra-Red spectrographic analysis technology platform to address significant healthcare needs, announced today topline interim results from a clinical study...
IR-Med to present at National Pressure Injury Advisory Panel 2023
The company's PressureSafe device is being designed to reduce healthcare disparity in pressure injury detection and treatment
IR-Med to Announce 2022 Goals: Anticipated POC Results, File for FDA Clearance and up Listing to the OTCQB
TEL AVIV, Israel--(BUSINESS WIRE)---- $IRME--IR-Med (OTC: IRME) (“Company” or “the Company”) is proud to announce a series of corporate updates to its investors regarding the medical, financial, and corporate status of the company. Amongst other things, IR-Med announces that starting...
IR-Med, Inc. Announces the Appointment of Dr. Rom Eliaz as Chief Executive Officer
New York, NY, June 25, 2021 (GLOBE NEWSWIRE) -- IR-Med, Inc. (OTCPINK: IRME) announced today the appointment of Dr. Rom Eliaz as Chief Executive Officer.
Source: https://incomestatements.info
Category: Stock Reports